BRKR Bruker Corporation
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.84
P/S
2.01
EV/EBITDA
26.77
DCF Value
$49.35
FCF Yield
0.7%
Div Yield
0.4%
Margins & Returns
Gross Margin
45.6%
Operating Margin
5.9%
Net Margin
-0.3%
ROE
-0.5%
ROA
-0.2%
ROIC
-2.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $823.4M | $14.4M | $— |
| Q4 null | $977.2M | $26.0M | $— |
| FY null | $3.44B | $-8.6M | $— |
| Q3 null | $860.5M | $-59.6M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$50.13
Target (Median)
$51.50
Target Range
$35.00 - $60.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.12
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.